Cargando…

Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy

SIMPLE SUMMARY: Hypoxia is found in half of the solid cancers and is a major contributor to treatment resistance and promotion of metastasis, leading to shortened patient survival. No user-friendly in vitro preclinical tool exists to study natural chronic hypoxia. The aim of this study was to design...

Descripción completa

Detalles Bibliográficos
Autores principales: Refet-Mollof, Elena, Najyb, Ouafa, Chermat, Rodin, Glory, Audrey, Lafontaine, Julie, Wong, Philip, Gervais, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394550/
https://www.ncbi.nlm.nih.gov/pubmed/34439199
http://dx.doi.org/10.3390/cancers13164046
_version_ 1783743974174883840
author Refet-Mollof, Elena
Najyb, Ouafa
Chermat, Rodin
Glory, Audrey
Lafontaine, Julie
Wong, Philip
Gervais, Thomas
author_facet Refet-Mollof, Elena
Najyb, Ouafa
Chermat, Rodin
Glory, Audrey
Lafontaine, Julie
Wong, Philip
Gervais, Thomas
author_sort Refet-Mollof, Elena
collection PubMed
description SIMPLE SUMMARY: Hypoxia is found in half of the solid cancers and is a major contributor to treatment resistance and promotion of metastasis, leading to shortened patient survival. No user-friendly in vitro preclinical tool exists to study natural chronic hypoxia. The aim of this study was to design a microfluidic device allowing easy culture, maintenance, treatment, and analysis of naturally hypoxic sarcoma spheroids. We confirmed that our jumbo spheroids (>750 µm) contained hypoxic cores, as they expressed the hypoxic marker protein Carbonic Anhydrase IX (CAIX). Quantification of DNA strand breaks from radiotherapy and a hypoxia pro-drug demonstrated hypoxia-dependent treatment responses. Our novel microfluidic device is versatile and convenient for both fundamental and preclinical research, to better understand and treat hypoxic tumors. ABSTRACT: Hypoxia is a key characteristic of the tumor microenvironment, too rarely considered during drug development due to the lack of a user-friendly method to culture naturally hypoxic 3D tumor models. In this study, we used soft lithography to engineer a microfluidic platform allowing the culture of up to 240 naturally hypoxic tumor spheroids within an 80 mm by 82.5 mm chip. These jumbo spheroids on a chip are the largest to date (>750 µm), and express gold-standard hypoxic protein CAIX at their core only, a feature absent from smaller spheroids of the same cell lines. Using histopathology, we investigated response to combined radiotherapy (RT) and hypoxic prodrug Tirapazamine (TPZ) on our jumbo spheroids produced using two sarcoma cell lines (STS117 and SK-LMS-1). Our results demonstrate that TPZ preferentially targets the hypoxic core (STS117: p = 0.0009; SK-LMS-1: p = 0.0038), but the spheroids’ hypoxic core harbored as much DNA damage 24 h after irradiation as normoxic spheroid cells. These results validate our microfluidic device and jumbo spheroids as potent fundamental and pre-clinical tools for the study of hypoxia and its effects on treatment response.
format Online
Article
Text
id pubmed-8394550
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83945502021-08-28 Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy Refet-Mollof, Elena Najyb, Ouafa Chermat, Rodin Glory, Audrey Lafontaine, Julie Wong, Philip Gervais, Thomas Cancers (Basel) Article SIMPLE SUMMARY: Hypoxia is found in half of the solid cancers and is a major contributor to treatment resistance and promotion of metastasis, leading to shortened patient survival. No user-friendly in vitro preclinical tool exists to study natural chronic hypoxia. The aim of this study was to design a microfluidic device allowing easy culture, maintenance, treatment, and analysis of naturally hypoxic sarcoma spheroids. We confirmed that our jumbo spheroids (>750 µm) contained hypoxic cores, as they expressed the hypoxic marker protein Carbonic Anhydrase IX (CAIX). Quantification of DNA strand breaks from radiotherapy and a hypoxia pro-drug demonstrated hypoxia-dependent treatment responses. Our novel microfluidic device is versatile and convenient for both fundamental and preclinical research, to better understand and treat hypoxic tumors. ABSTRACT: Hypoxia is a key characteristic of the tumor microenvironment, too rarely considered during drug development due to the lack of a user-friendly method to culture naturally hypoxic 3D tumor models. In this study, we used soft lithography to engineer a microfluidic platform allowing the culture of up to 240 naturally hypoxic tumor spheroids within an 80 mm by 82.5 mm chip. These jumbo spheroids on a chip are the largest to date (>750 µm), and express gold-standard hypoxic protein CAIX at their core only, a feature absent from smaller spheroids of the same cell lines. Using histopathology, we investigated response to combined radiotherapy (RT) and hypoxic prodrug Tirapazamine (TPZ) on our jumbo spheroids produced using two sarcoma cell lines (STS117 and SK-LMS-1). Our results demonstrate that TPZ preferentially targets the hypoxic core (STS117: p = 0.0009; SK-LMS-1: p = 0.0038), but the spheroids’ hypoxic core harbored as much DNA damage 24 h after irradiation as normoxic spheroid cells. These results validate our microfluidic device and jumbo spheroids as potent fundamental and pre-clinical tools for the study of hypoxia and its effects on treatment response. MDPI 2021-08-11 /pmc/articles/PMC8394550/ /pubmed/34439199 http://dx.doi.org/10.3390/cancers13164046 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Refet-Mollof, Elena
Najyb, Ouafa
Chermat, Rodin
Glory, Audrey
Lafontaine, Julie
Wong, Philip
Gervais, Thomas
Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy
title Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy
title_full Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy
title_fullStr Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy
title_full_unstemmed Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy
title_short Hypoxic Jumbo Spheroids On-A-Chip (HOnAChip): Insights into Treatment Efficacy
title_sort hypoxic jumbo spheroids on-a-chip (honachip): insights into treatment efficacy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394550/
https://www.ncbi.nlm.nih.gov/pubmed/34439199
http://dx.doi.org/10.3390/cancers13164046
work_keys_str_mv AT refetmollofelena hypoxicjumbospheroidsonachiphonachipinsightsintotreatmentefficacy
AT najybouafa hypoxicjumbospheroidsonachiphonachipinsightsintotreatmentefficacy
AT chermatrodin hypoxicjumbospheroidsonachiphonachipinsightsintotreatmentefficacy
AT gloryaudrey hypoxicjumbospheroidsonachiphonachipinsightsintotreatmentefficacy
AT lafontainejulie hypoxicjumbospheroidsonachiphonachipinsightsintotreatmentefficacy
AT wongphilip hypoxicjumbospheroidsonachiphonachipinsightsintotreatmentefficacy
AT gervaisthomas hypoxicjumbospheroidsonachiphonachipinsightsintotreatmentefficacy